Overview
Description
Absci Corporation operates at the cutting edge of synthetic biology and drug discovery. As a biotechnology company, its primary function is to harness the power of artificial intelligence and synthetic biology to expedite the discovery and development of therapeutic proteins. By integrating machine learning with its proprietary synthetic biology platform, Absci aims to revolutionize how pharmaceuticals are designed, developed, and manufactured. This innovative approach holds significant promise for the healthcare and biotech industries, including enabling more efficient drug development processes and potentially uncovering new therapeutic pathways. Based in Vancouver, Washington, Absci Corporation serves as a vital player in the quest to transform biopharmaceuticals, ensuring more rapid and cost-effective delivery of medicines. The company's commitment to innovation situates it as a transformative entity within the global healthcare and life sciences sectors, offering scalable solutions that could set new benchmarks in the industry.
About
CEO
Mr. Sean McClain
Employees
156
Address
18105 SE Mill Plain Boulevard
Vancouver, 98683, WA
United States
Vancouver, 98683, WA
United States
Phone
360 949 1041
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNGS